Celiac Disease Treatment

Global Celiac Disease Treatment Market to Reach US$1.1 Billion by 2030

The global market for Celiac Disease Treatment estimated at US$597.1 Million in the year 2024, is expected to reach US$1.1 Billion by 2030, growing at a CAGR of 11.2% over the analysis period 2024-2030. Vitamins & Minerals Treatment, one of the segments analyzed in the report, is expected to record a 12.9% CAGR and reach US$586.8 Million by the end of the analysis period. Growth in the Gluten-Free Diet Treatment segment is estimated at 10.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$162.7 Million While China is Forecast to Grow at 15.5% CAGR

The Celiac Disease Treatment market in the U.S. is estimated at US$162.7 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$237.5 Million by the year 2030 trailing a CAGR of 15.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.9% and 10.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.9% CAGR.

Global Celiac Disease Treatment Market – Key Trends & Drivers Summarized

Why Is the Demand for Celiac Disease Treatment Increasing?

The demand for celiac disease treatment is increasing due to rising awareness of gluten-related disorders, improved diagnostic techniques, and a growing prevalence of celiac disease worldwide. Celiac disease is an autoimmune condition triggered by gluten consumption, leading to intestinal damage, malabsorption, and a range of health complications. As more individuals are diagnosed with the condition, there is an increasing demand for effective treatment options beyond a strict gluten-free diet.

The availability of advanced diagnostic tests has led to earlier and more accurate identification of celiac disease, expanding the patient pool requiring treatment. Additionally, growing consumer awareness about gluten sensitivity and the long-term health risks associated with undiagnosed celiac disease has increased the demand for medical intervention. Research into novel therapies, including enzyme-based treatments, immunotherapies, and gut microbiome modulation, is gaining momentum, providing new hope for patients seeking alternatives to lifelong dietary restrictions.

How Are Technological Advancements Improving Celiac Disease Treatment?

Innovations in biotechnology, precision medicine, and therapeutic drug development are transforming celiac disease treatment by offering new solutions beyond gluten avoidance. One of the most significant advancements is the development of oral enzyme therapies designed to break down gluten in the digestive tract before it triggers an immune response. These enzyme-based treatments are being designed to help patients manage accidental gluten exposure, reducing symptoms and intestinal damage.

Another breakthrough is the exploration of immune-modulating drugs that can alter the body’s reaction to gluten. Researchers are developing therapies that aim to retrain the immune system to tolerate gluten or block the inflammatory response that causes intestinal damage. Additionally, advancements in gut microbiome research have opened new possibilities for probiotic-based treatments that promote a healthier intestinal environment and reduce celiac-related inflammation. The integration of genetic screening tools is also improving early diagnosis and personalized treatment approaches, ensuring more effective management of the disease.

Which Market Trends Are Driving Growth in the Celiac Disease Treatment Industry?

The increasing consumer demand for gluten-free pharmaceuticals and dietary supplements is one of the most influential trends shaping the celiac disease treatment market. As awareness grows about the impact of cross-contamination and hidden gluten in food and medications, there is a greater emphasis on developing certified gluten-free medical products. This trend is driving pharmaceutical companies to ensure that medications, vitamins, and other treatments are safe for individuals with celiac disease.

Another key trend influencing market growth is the expansion of clinical trials for disease-modifying drugs. Several pharmaceutical companies are actively conducting trials for vaccines, biologics, and enzyme-based therapies that aim to provide long-term relief for celiac disease patients. Additionally, the integration of digital health platforms and mobile apps for diet management and symptom tracking is helping patients manage their condition more effectively. As the regulatory landscape evolves, the approval of novel celiac disease treatments is expected to accelerate, providing more comprehensive care options beyond dietary modifications.

What Are the Key Growth Drivers Shaping the Future of the Celiac Disease Treatment Market?

The growth in the celiac disease treatment market is driven by several factors, including increased research funding, rising diagnosis rates, and advancements in therapeutic innovation. One of the primary growth drivers is the expanding role of pharmaceutical and biotech companies in developing targeted therapies that go beyond gluten-free diets. With strong investments in clinical trials and drug discovery, the pipeline for celiac disease treatments is steadily growing.

Another crucial driver shaping the market is the increasing government and healthcare initiatives to improve awareness and early detection. Many countries are implementing screening programs and patient education campaigns to reduce the burden of undiagnosed celiac disease. Additionally, collaborations between food companies and pharmaceutical firms are leading to the development of more effective gluten detection tools and safer dietary solutions. As science continues to uncover new treatment pathways, the future of celiac disease management will likely include a combination of personalized medicine, dietary support, and pharmaceutical intervention, ensuring better quality of life for patients worldwide.

SCOPE OF STUDY:

The report analyzes the Celiac Disease Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Treatment (Vitamins and Minerals Treatment, Gluten-Free Diet Treatment, Medical Therapies Treatment); Route of Administration (Oral Route of Administration, Parenteral Route of Administration); Distribution Channel (Hospitals Distribution Channels, Research Centers Distribution Channels, Other Distribution Channels)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• 9 Meters Biopharma, Inc.
• Anokion SA
• Barinthus Biotherapeutics
• Chugai Pharmaceutical Co., Ltd.
• Cour Pharmaceuticals
• Equillium, Inc.
• Falk Pharma GmbH
• Immunic, Inc.
• ImmunogenX
• Mozart Therapeutics
• Nemysis Ltd
• Novartis AG
• Pfizer Inc.
• Precigen ActoBio
• Protagonist Therapeutics, Inc.
• Provention Bio, Inc.
• Sanofi
• Takeda Pharmaceutical Company Limited
• Theriva Biologics
• Zedira GmbH

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.